The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use 1µl for 106 cells. Characterization of leukemias in human lysed whole peripheral blood or mononuclear cells separated by density gradient.
Identification of HLA DR tumors.
HLA-DR (FITC) immunofluorescence analysis can be performed on a flow cytometerequipped with an excitation source of 488nm and fitted with logarithmic amplifiers.
FunctionBinds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
Sequence similaritiesBelongs to the MHC class II family. Contains 1 Ig-like C1-type (immunoglobulin-like) domain.
Post-translational modificationsUbiquitinated by MARCH1 or MARCH8 at Lys-244 leading to down-regulation of MHC class II. When associated with ubiquitination of the beta subunit of HLA-DR: HLA-DRB4 'Lys-254', the down-regulation of MHC class II may be highly effective.
Cellular localizationCell membrane. Endoplasmic reticulum membrane. Golgi apparatus > trans-Golgi network membrane. Endosome membrane. Lysosome membrane. Late endosome membrane. The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation.
HLA class II histocompatibility antigen DR alpha chain antibody
HLA DR1B antibody
HLA DR3B antibody
HLA DRA antibody
HLA DRA1 antibody
HLA DRB1 antibody
HLA DRB3 antibody
HLA DRB4 antibody
HLA DRB5 antibody
Major histocompatibility complex class II DR alpha antibody
Major histocompatibility complex class II DR beta 1 antibody
Major histocompatibility complex class II DR beta 3 antibody
Major histocompatibility complex class II DR beta 4 antibody
Major histocompatibility complex class II DR beta 5 antibody
MHC cell surface glycoprotein antibody
MHC class II antigen DRA antibody
MHC II antibody
Anti-HLA DR antibody [LN3] (FITC) images
Flow Cytometry - Anti-HLA DR antibody [LN3] (FITC) (ab1182)
Overlay histogram showing peripheral blood lymphocytes stained with ab1182 (red line). The cells incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab1182, 0.01 µg/1x106 cells) for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG2b FITC (0.1 µg/1x106 cells ) for 30 min at 22°C. Acquisition of >5,000 events was performed.
References for Anti-HLA DR antibody [LN3] (FITC) (ab1182)
This product has been referenced in:
Andrade RE et al. Distribution and immunophenotype of the inflammatory cell population in the benign lymphoepithelial lesion (Mikulicz's disease). Hum Pathol19:932-41 (1988).
Read more (PubMed: 3402982) »
Azumi N et al. Antigenic phenotype of Langerhans cell histiocytosis: an immunohistochemical study demonstrating the value of LN-2, LN-3, and vimentin. Hum Pathol19:1376-82 (1988).
Read more (PubMed: 2973428) »